{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:29:49Z","timestamp":1757618989689,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2020,10,20]]},"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1136\/ejhpharm-2020-002293","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T17:20:35Z","timestamp":1605547235000},"page":"290-293","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Elevation of transaminases associated with teriparatide treatment: a case report"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-714X","authenticated-orcid":false,"given":"Francesco","family":"Pappalardo","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Ospedale degli Infermi di Rimini, Rimini, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fantini","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ospedale degli Infermi di Rimini, Rimini, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Caruso","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, St Thomas' Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"2025090703040557000_29.5.290.1","first-page":"2","article-title":"Osteoporosis: epidemiology, diagnosis, and treatment","volume":"93","author":"Iqbal","year":"2000","journal-title":"South Med J"},{"key":"2025090703040557000_29.5.290.2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1302\/2058-5241.4.180018","article-title":"Molecular understanding of pharmacological treatment of osteoporosis","volume":"4","author":"Tanaka","year":"2019","journal-title":"EFORT Open Rev"},{"key":"2025090703040557000_29.5.290.3","first-page":"1073","article-title":"Teriparatide in the treatment of severe postmenopausal osteoporosis: a cost-utility analysis","volume":"18","author":"Taheri","year":"2019","journal-title":"Iran J Pharm Res"},{"key":"2025090703040557000_29.5.290.4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013341","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis","volume":"97","author":"Deng","year":"2018","journal-title":"Medicine"},{"key":"2025090703040557000_29.5.290.5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","article-title":"Teriparatide for osteoporosis: importance of the full course","volume":"27","author":"Lindsay","year":"2016","journal-title":"Osteoporos Int"},{"key":"2025090703040557000_29.5.290.6","doi-asserted-by":"crossref","DOI":"10.11005\/jbm.2018.25.3.133","article-title":"Treatment of osteoporosis: unmet needs and emerging solutions","volume":"25","author":"Langdahl","year":"2018","journal-title":"J Bone Metab"},{"key":"2025090703040557000_29.5.290.7","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0006"},{"key":"2025090703040557000_29.5.290.8","unstructured":"LiverTox . Teriparatide. In: Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548722\/"},{"key":"2025090703040557000_29.5.290.9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/bcp.13766","article-title":"Osteoanabolic and dual action drugs","volume":"85","author":"Tabacco","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2025090703040557000_29.5.290.10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/js.2018-00118","article-title":"Osteoanabolic agents for osteoporosis","volume":"2","author":"Haas","year":"2018","journal-title":"J Endocr Soc"},{"key":"2025090703040557000_29.5.290.11","unstructured":"European Medicines Agency . Forsteo European public assessment report (EPAR). Available: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/forsteo-epar-summary-public_en.pdf"},{"key":"2025090703040557000_29.5.290.12","unstructured":"Eli Lilly and Company . Forsteo FDA label. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021318s012lbl.pdf"},{"key":"2025090703040557000_29.5.290.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.02.015"},{"key":"2025090703040557000_29.5.290.14","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-012-1927-8","article-title":"De novo autoimmune hepatitis associated with PTH(1-34) and PTH(1-84) administration for severe osteoporosis in a liver transplant patient: reply to Aguilera and Nu\u00f1ez-Roldan","volume":"23","author":"Anagnostis","year":"2012","journal-title":"Osteoporos Int"},{"key":"2025090703040557000_29.5.290.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eujim.2020.101164","article-title":"Drug induced liver injury (DILI) due to variability in monacolin K content in red yeast rice (RyR): an expert opinion","volume":"37","author":"Cicero","year":"2020","journal-title":"Eur J Integr Med"},{"key":"2025090703040557000_29.5.290.16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40264-018-0661-3","article-title":"Adverse events to food supplements containing red yeast rice: comparative analysis of FAERS and CAERS reporting systems","volume":"41","author":"Raschi","year":"2018","journal-title":"Drug Saf"},{"key":"2025090703040557000_29.5.290.17","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bcp.13171","article-title":"Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system","volume":"83","author":"Mazzanti","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025090703040557000_29.5.290.18","unstructured":"LiverTox . Causality. In: Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548049\/"},{"key":"2025090703040557000_29.5.290.19","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-227961","article-title":"Acute liver injury induced by red yeast rice supplement","volume":"12","author":"Loubser","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2025090703040557000_29.5.290.20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jhep.2009.02.021","article-title":"Acute hepatitis caused by a natural lipid-lowering product: when \"alternative\" medicine is no \"alternative\" at all","volume":"50","author":"Grieco","year":"2009","journal-title":"J Hepatol"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2020-002293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:04:14Z","timestamp":1757239454000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2020-002293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,8,23]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/ejhpharm-2020-002293"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2020-002293","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2020,11,16]]}}}